Zobrazeno 1 - 10
of 137
pro vyhledávání: '"Ala Yaromina"'
Autor:
Lydia Koi, Verena Bitto, Corina Weise, Lisa Möbius, Annett Linge, Steffen Löck, Ala Yaromina, María José Besso, Chiara Valentini, Manuel Pfeifer, Jens Overgaard, Daniel Zips, Ina Kurth, Mechthild Krause, Michael Baumann
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-17 (2023)
Abstract Background Tumor hypoxia is associated with resistance to radiotherapy and chemotherapy. In head and neck squamous cell carcinoma (HNSCC), nimorazole, an oxygen mimic, combined with radiotherapy (RT) enabled to improve loco-regional control
Externí odkaz:
https://doaj.org/article/ef4ef6625b6940398e45aefa8c370d20
Autor:
Jurgita Matulienė, Gediminas Žvinys, Vytautas Petrauskas, Agnė Kvietkauskaitė, Audrius Zakšauskas, Kirill Shubin, Asta Zubrienė, Lina Baranauskienė, Lina Kačenauskaitė, Sergei Kopanchuk, Santa Veiksina, Vaida Paketurytė-Latvė, Joana Smirnovienė, Vaida Juozapaitienė, Aurelija Mickevičiūtė, Vilma Michailovienė, Jelena Jachno, Dovilė Stravinskienė, Aistė Sližienė, Agnė Petrošiūtė, Holger M. Becker, Justina Kazokaitė-Adomaitienė, Ala Yaromina, Edita Čapkauskaitė, Ago Rinken, Virginija Dudutienė, Ludwig J Dubois, Daumantas Matulis
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-25 (2022)
Abstract Numerous human cancers, especially hypoxic solid tumors, express carbonic anhydrase IX (CAIX), a transmembrane protein with its catalytic domain located in the extracellular space. CAIX acidifies the tumor microenvironment, promotes metastas
Externí odkaz:
https://doaj.org/article/37ebb5e55c0a4123a7c8f686b66ab087
Autor:
Relinde I. Y. Lieverse, Damiënne Marcus, Alexander M. A. van derWiel, Evert J. Van Limbergen, Jan Theys, Ala Yaromina, Philippe Lambin, Ludwig J. Dubois
Publikováno v:
Molecular Oncology, Vol 14, Iss 7, Pp 1555-1568 (2020)
The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid tumours, different types of lymphoma and some le
Externí odkaz:
https://doaj.org/article/1f3cad2547ba48c08f6f7fe3f8a7f267
Autor:
Relinde I. Y. Lieverse, Evert J. Van Limbergen, Cary J. G. Oberije, Esther G. C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E. L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, Yolande Lievens, Monique C. de Jong, Johan Bussink, Xavier Geets, Vincenzo Valentini, Giuliano Elia, Dario Neri, Charlotte Billiet, Amir Abdollahi, David Pasquier, Pierre Boisselier, Ala Yaromina, Dirk De Ruysscher, Ludwig J. Dubois, Philippe Lambin
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), eit
Externí odkaz:
https://doaj.org/article/3d19c81b16c745a58482aa1902edf103
Autor:
Bart J.T. Reymen, Marike W. van Gisbergen, Aniek J.G. Even, Catharina M.L. Zegers, Marco Das, Erik Vegt, Joachim E. Wildberger, Felix M. Mottaghy, Ala Yaromina, Ludwig J. Dubois, Wouter van Elmpt, Dirk De Ruysscher, Philippe Lambin
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 21, Iss , Pp 49-55 (2020)
Background: Nitroglycerin is proposed as an agent to reduce tumour hypoxia by improving tumour perfusion. We investigated the potential of nitroglycerin as a radio-sensitizer in non-small cell lung cancer (NSCLC) and the potential of functional imagi
Externí odkaz:
https://doaj.org/article/d8f668cc42714be38f759f1da0d06f22
Autor:
Cameron Meaney, Gibin G Powathil, Ala Yaromina, Ludwig J Dubois, Philippe Lambin, Mohammad Kohandel
Publikováno v:
Mathematical Biosciences and Engineering, Vol 16, Iss 6, Pp 6257-6273 (2019)
Tumour hypoxia has been associated with increased resistance to various cancer treatments, particularly radiation therapy. Conversely, tumour hypoxia is a validated and ideal target for guided cancer drug delivery. For this reason, hypoxia-activated
Externí odkaz:
https://doaj.org/article/695c4a524be740aab3b05762b9e9ada8
Autor:
Linda Spiegelberg, Ruud Houben, Raymon Niemans, Dirk de Ruysscher, Ala Yaromina, Jan Theys, Christopher P. Guise, Jeffrey B. Smaill, Adam V. Patterson, Philippe Lambin, Ludwig J. Dubois
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 15, Iss , Pp 62-69 (2019)
Hypoxia-activated prodrugs (HAPs) are designed to specifically target the hypoxic cells of tumors, which are an important cause of treatment resistance to conventional therapies. Despite promising preclinical and clinical phase I and II results, the
Externí odkaz:
https://doaj.org/article/75c6748e20a543519df6ae43fdf0f2f0
Autor:
Veronica Olivo Pimentel, Damiënne Marcus, Alexander MA van der Wiel, Natasja G Lieuwes, Rianne Biemans, Relinde IY Lieverse, Dario Neri, Jan Theys, Ala Yaromina, Ludwig J Dubois, Philippe Lambin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Poorly immunogenic tumors are hardly responsive to immunotherapies such as immune checkpoint blockade (ICB) and are, therefore, a therapeutic challenge. Combination with other immunotherapies and/or immunogenic therapies, such as radiother
Externí odkaz:
https://doaj.org/article/79cc56a05cf2418c8eb72e923bf9ce7a
Autor:
Sara Hamis, Mohammad Kohandel, Ludwig J Dubois, Ala Yaromina, Philippe Lambin, Gibin G Powathil
Publikováno v:
PLoS Computational Biology, Vol 16, Iss 8, p e1008041 (2020)
Hypoxia-activated prodrugs (HAPs) present a conceptually elegant approach to not only overcome, but better yet, exploit intra-tumoural hypoxia. Despite being successful in vitro and in vivo, HAPs are yet to achieve successful results in clinical sett
Externí odkaz:
https://doaj.org/article/b90574be2a08420ab8f7d1a3f4598e5d
Autor:
Philippe Lambin, Ludwig J. Dubois, Wouter van Elmpt, Albert D. Windhorst, Charles P. Hart, Jessica D. Sun, Ala Yaromina, Ruud G.P.M. van Stiphout, Natasja G. Lieuwes, Rianne Biemans, Catharina M.L. Zegers, Sarah G.J.A. Peeters
Supplementary Table 2. Time to reach 4 times start volume per treatment group for H460 bearing animals. Data represent mean {plus minus} SD, p-value and sensitization enhancement ratio.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f805bf8020ef756cd7e2b6ea21878d8
https://doi.org/10.1158/1078-0432.22456653
https://doi.org/10.1158/1078-0432.22456653
